Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response

Executive Summary

BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.

You may also be interested in...



Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience

Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements  –  provides the framework to mitigate against and respond to drug shortages.

US Supply Chain "Elasticity" Pilot Would Get Major Funds In House-Passed Legislation

COMPETES Act also includes enhanced penalties for drug makers who falsify or destroy records, power for the FDA to recall harmful drugs, funding for drug manufacturing technology and additional supply chain flexibility efforts.

US Senate Measure Highlights ‘Warm-Base’ Manufacturing Capacity For Next Pandemic Response

Committee's bipartisan discussion draft for legislation outlines lessons learned from COVID-19 pandemic response, including need for greater manufacturing facility readiness. Meanwhile, congressional oversight agency calls for “transformation” of response efforts.

Topics

UsernamePublicRestriction

Register

PS145580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel